Mechanism of action in thalidomide teratogenesis

Biochemical Pharmacology

Volumn 59, Issue 12, 2000, Pages 1489-1499

  Stephens, Trent D ^a   Bunde, Carolyn J W ^a   Fillmore, Bradley J ^a  

^a Nucl Eng Idaho State University   (United States)

Author keywords

DNA intercalation; Growth factors; Integrins; Limb defects; Thalidomide

Indexed keywords

BETA3 INTEGRIN; FIBROBLAST GROWTH FACTOR 2; INTEGRIN; PROTEIN SUBUNIT; SOMATOMEDIN C; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BINDING SITE; DNA BINDING; ENANTIOMER; FETUS; GENE STRUCTURE; HUMAN; LIMB DEFECT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; TERATOGENESIS; TERATOGENICITY; TRANSCRIPTION REGULATION;

EID: 0034060666     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00388-3     Document Type: Article

References (176)

1. Stephens T.D., Fillmore B.J. Hypothesis Thalidomide embryopathy - Proposed mechanism of action . Teratology. 61:2000;189-195.
2. McBride WB, Thalidomide and congenital abnormalities. Lancet ii: 1358, 1961.
3. Lenz W, Thalidomide and congenital abnormalities. Lancet i: 45, 1962.
4. Lenz W., Knapp K. Die Thalidomida Embrypathie. Dtsch Med Wochenschr. 87:1962;1232.
5. Taussig H.B. The thalidomide syndrome. Sci Am. 207:1962;29-35.
6. Lenz W. A short history of thalidomide embryopathy. Teratology. 38:1988;203-215.
7. Koch H.P. Comments on, "proposed mechanisms of action in thalidomide embryopathy." Teratology. 41:1990;243-244.
8. Stephens T.D. Response to Comments on "proposed mechanisms of action in thalidomide embryopathy. " Teratology. 41:1990;245-246.
9. http://www.nlm.nih.gov/pubs/cbm/thalidomide.html.
10. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 6:1965;303-306.
11. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 173:1991;699-703.
12. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 177:1993;1675-1680.
13. Hellmann K, Immunosuppression by thalidomide: Implications for teratology. Lancet i: 1136-1137, 1966.
14. Heney D., Norfolk D.R., Wheeldon J., Bailey C.C., Lewis I.J., Barnard D.L. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol. 78:1991;23-27.
15. Vogelsang G.B., Farmer E.R., Hess A.D., Altamonte V., Beschorner W.E., Jabs D.A., Corio R.L., Levin L.S., Colvin O.M., Wingard J.R. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 326:1992;1055-1058.
16. Vogelsang G.B. Acute and chronic graft-versus-host disease. Curr Opin Oncol. 5:1993;276-281.
17. Cole C.H., Rogers P.C., Pritchard S., Phillips G., Chan K.W. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant. 14:1994;937-942.
18. Tramontana J.M., Utaipat U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., Johnson B., Klausner J.D., Rom W., Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1:1995;384-397.
19. Shannon E.J., Ejigu M., Haile-Mariam H.S., Berhan T.Y., Tasesse G. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev. 63:1992;5-11.
20. Makonkawkeyoon S., Limson-Probre R.N., Moreira A.L., Schauf V., Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 90:1993;5974-5978.
21. Klausner J.D., Freedman V.H., Kaplan G. Thalidomide as an anti-TNF-α inhibitor Implications for clinical use . Clin Immunol Immunopathol. 81:1996;219-223.
22. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:1994;4082-4085.
23. Castilla E.E., Ashton-Prolla P., Barreda-Mejia E., Brunoni D., Cavalcanti D.P., Correa-Neto J., Delgadillo J.L., Dutra M.G., Felix T., Giraldo A., Juarez N., Lopez-Camelo J.S., Nazer J., Orioli I.M., Paz J.E., Pessoto M.A., Pina-Neto J.M., Quadrelli R., Rittler M., Rueda S., Saltos M., Sanchez O., Schuler L. Thalidomide, a current teratogen in South America. Teratology. 54:1996;273-277.
24. Stephens T.D. Proposed mechanisms of action in thalidomide embryopathy. Teratology. 38:1988;229-239.
25. Neubert R., Hinz N., Thiel R., Neubert D. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58:1996;295-316.
26. Wells P.G., Kim P.M., Laposa R.R., Nicol C.J., Parman T., Winn L.M. Oxidative damage in chemical teratogenesis. Mutat Res. 396:1997;65-78.
27. Parman T., Wiley M.J., Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 5:1999;582-585.
28. Ashby J., Tinwell H., Callander R.D., Kimber I., Clay P., Galloway S.M., Hill R.B., Greenwood S.K., Gaulden M.E., Ferguson M.J., Vogel E., Nivard M., Parry J.M., Williamson J. Thalidomide Lack of mutagenic activity across phyla and genetic endpoints . Mutat Res. 396:1997;45-64.
29. Argiles J.M., Carbo N., Lopez-Soriano F.J. Was tumour necrosis factor-α responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses. 50:1998;313-318.
30. Barnes P.F., Chatterjee D., Brennan P.J., Rea T.H., Modlin R.L. Tumor necrosis factor production in patients with leprosy. Infect Immun. 60:1992;1441-1446.
31. Kenyon B.M., Browne F., D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 64:1997;971-978.
32. Tabin C.J. A developmental model for thalidomide defects. Nature. 396:1998;322-323.
33. Stephens T.D., Bunde C.J.W., Torres R.D., Hackett D.A., Stark M.R., Smith D.M., Fillmore B.J. Thalidomide inhibits limb development through its antagonism of IGF-I+FGF-2+heparin. Teratology. 57:1998;112.
34. Hamburger V., Hamilton H.L. A series of normal stages in the development of the chick embryo. J Morphol. 88:1951;49-92.
35. Stephens T.D., Beier R.L.W., Bringhurst D.C., Hiatt S.R., Prestridge M., Pugmire D.E., Willis H.J. Limbness in the early chick embryo lateral plate. Dev Biol. 133:1989;1-7.
36. Jönsson N.A. Chemical structure and teratogenic properties. IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. Acta Pharm Suec. 9:1972;543-562.
37. Kohler F., Fickentscher K., Halfmann U., Koch H. Embryotoxicity and teratogenicity of derivatives of 1,3-indandion. Arch Toxicol. 33:1975;191-197.
38. Fickentscher K., Kohler F. Teratogenicity and embryotoxicity of some maleinimides. Arch Toxicol. 37:1976;15-21.
39. Koch H.P., Czejka M.J. Evidence for the intercalation of thalidomide into DNA Clue to the molecular mechanism of thalidomide teratogenicity? Z Naturforsch [C]. 41:1986;1057-1061.
40. 14C]-thalidomide with rat embryonic DNA in vivo. Teratog Carcinog Mutagen. 17:1997;1-5.
41. Blaschke G., Kraft H.P., Fickentscher F., Köhler F. Chromatographische Racemattrennung von Thalidomid und Teratogene Wirkung der Enantiomere. Arzneimittelforschung. 29:1979;1640-1642.
42. Helm F.C., Frankus E., Friderichs E., Graudums I., Flohe L. Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide. Arzneimittelforschung. 31:1981;941-949.
43. Bucher P. Weight matrix descriptions of four eukaryotic RNA polymerase II promoter elements derived from 502 unrelated promoter sequences. J Mol Biol. 212:1990;563-578.
44. Dynan W.S., Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 35:1983;79-87.
45. Jackson S.P., MacDonald J.J., Lees-Miller S., Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell. 63:1990;155-165.
46. Narayan V.A., Kriwacki R.W., Caradonna J.P. Structures of zinc finger domains from transcription factor Sp1. Insights into sequence-specific protein-DNA recognition. J Biol Chem. 272:1997;7801-7809.
47. Pavletich N.P., Pabo C.O. Zinc finger-DNA recognition Crystal structure of a Zif268-DNA complex at 2.1 Å Science. 252:1991;809-817.
48. Isalan M., Klug A., Choo Y. Comprehensive DNA recognition through concerted interactions from adjacent zinc fingers. Biochemistry. 37:1998;12026-12033.
49. Matsushita K., Hagihara M., Sugiura Y. Participation of oligomerization through C-terminal D domain region of Sp1 in DNA binding. Biol Pharm Bull. 21:1998;1094-1097.
50. Nolte R.T., Conlin R.M., Harrison S.C., Brown R.S. Differing roles for zinc fingers in DNA recognition Structure of a six-finger transcription factor IIIA complex . Proc Natl Acad Sci USA. 95:1998;2938-2943.
51. Ji C., Casinghino S., McCarthy T.L., Centrella M. Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-β type I receptor. J Biol Chem. 272:1997;21260-21267.
52. Noti J.D., Reinemann B.C., Petrus M.N. Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription. Mol Cell Biol. 16:1996;2940-2950.
53. Chen H.M., Pahl H.L., Scheibe R.J., Zhang D.E., Tenen D.G. The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid-specific promoter activity. J Biol Chem. 268:1993;8230-8239.
54. Gidoni D., Dynan W.S., Tjian R. Multiple specific contacts between a mammalian transcription factor and its cognate promoters. Nature. 312:1984;409-413.
55. Dynan W.S., Saffer J.D., Lee W.S., Tjian R. Transcription factor Sp1 recognizes promoter sequences from the monkey genome that are simian virus 40 promoter. Proc Natl Acad Sci USA. 82:1985;4915-4919.
56. Gidoni D., Kadonaga J.T., Barrera-Saldana H., Takahashi K., Chambon P., Tjian R. Bidirectional SV40 transcription mediated by tandem Sp1 binding interactions. Science. 230:1985;511-517.
57. Courey A.J., Holtzman D.A., Jackson S.P., Tjian R. Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell. 59:1989;827-836.
58. Block K.L., Shou Y., Poncz M. An Ets/Sp1 interaction in the 5′-flanking region of the megakaryocyte-specific αIIb gene appears to stabilize Sp1 binding and is essential for expression of this TATA-less gene. Blood. 88:1996;2071-2080.
59. Rodenburg R.J., Holthuizen P.E., Sussenbach J.S. A functional Sp1 binding site is essential for the activity of the adult liver-specific human insulin-like growth factor II promoter. Mol Endocrinol. 11:1997;237-250.
60. Rotwein P., Pollock K.M., Watson M., Milbrandt J.D. Insulin-like growth factor gene expression during rat embryonic development. Endocrinology. 121:1987;2141-2144.
61. Kikuchi K., Buonomo F.C., Kajimoto Y., Rotwein P. Expression of insulin-like growth factor-I during chicken development. Endocrinology. 128:1991;1323-1328.
62. Scavo L.M., Serrano J., Roth J., de Pablo F. Genes for the insulin receptor and the insulin-like growth factor I receptor are expressed in the chicken embryo blastoderm and throughout organogenesis. Biochem Biophys Res Commun. 176:1991;1393-1401.
63. Ralphs J.R., Wylie L., Hill D.J. Distribution of insulin-like growth factor peptides in the developing chick embryo. Development. 109:1990;51-58.
64. Jacobs D.B., Ireland M., Pickett T., Maisel H., Grunberger G. Functional characterization of insulin and IGF-I receptors in chicken lens epithelial and fiber cells. Curr Eye Res. 11:1992;1137-1145.
65. Hansson H.A., Brandsten C., Lossing C., Petruson K. Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol. 50:1989;125-138.
66. Nakao-Hayashi J., Ito H., Kanayasu T., Morita I., Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis. 92:1992;141-149.
67. Streck R.D., Wood T.L., Hsu M.S., Pintar J.E. Insulin-like growth factor I and II and insulin-like growth factor binding protein-2 RNAs are expressed in adjacent tissues within rat embryonic and fetal limbs. Dev Biol. 151:1992;586-596.
68. Geduspan J.S., Solursh M. A growth-promoting influence from the mesonephros during limb outgrowth. Dev Biol. 151:1992;242-250.
69. Geduspan J.S., Solursh M. Effects of the mesonephros and insulin-like growth factor I on chondrogenesis of limb explants. Dev Biol. 156:1993;500-508.
70. Geduspan J.S., Padanilam B.J., Solursh M. Coordinate expression of IGF-I and its receptor during limb outgrowth. Dev Dyn. 195:1992;67-73.
71. Geduspan J.S., Padanilam B.J., Solursh M. Mesonephros derived IGF I in early limb development. Prog Clin Biol Res. 383B:1993;673-681.
72. Grant M.B., Mames R.N., Fitzgerald C., Ellis E.A., Aboufriekha M., Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina Comparative studies with basic fibroblast growth factor . Diabetologia. 36:1993;282-291.
73. Nicosia R.F., Nicosia S.V., Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol. 145:1994;1023-1029.
74. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res. 30:1995;825-834.
75. Kluge A., Zimmermann R., Munkel B., Mohri M., Sack S., Schaper J., Schaper W. Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res. 29:1995;407-415.
76. Dealy C.N., Kosher R.A. Studies on insulin-like growth factor-I and insulin in chick limb morphogenesis. Dev Dyn. 202:1995;67-79.
77. Dealy C.N., Kosher R.A. IGF-I and insulin in the acquisition of limb-forming ability by the embryonic lateral plate. Dev Biol. 177:1996;291-299.
78. Cooke D.W., Bankert L.A., Roberts C.T. Jr, LeRoith D., Casella S.J. Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun. 177:1991;1113-1120.
79. Niswander L., Martin G.R. FGF-4 and BMP-2 have opposite effects on limb growth. Nature. 361:1993;68-71.
80. Niswander L., Tickle C., Vogel A., Booth I., Martin G.R. FGF-4 replaces the apical ectodermal ridge and directs outgrowth and patterning of the limb. Cell. 75:1993;579-587.
81. Watanabe A., Ide H. Basic FGF maintains some characteristics of the progress zone of chick limb bud in cell culture. Dev Biol. 159:1993;223-231.
82. Niswander L., Tickle C., Vogel A., Martin G. Function of FGF-4 in limb development. Mol Reprod Dev. 39:1994;83-88.
83. Laufer E., Nelson C.E., Johnson R.L., Morgan B.A., Tabin C. Sonic hedgehog and Fgf-4 act through a signaling cascade and feedback loop to integrate growth and patterning of the developing limb bud. Cell. 79:1994;993-1003.
84. Fallon J.F., Lopez A., Ros M.A., Savage M.P., Olwin B.B., Simandl B.K. FGF-2, Apical ectodermal ridge growth signal for chick limb development. Science. 264:1994;104-107.
85. Mahmood R., Bresnick J., Hornbruch A., Mahony C., Morton N., Colquhoun K., Martin P., Lumsden A., Dickson C., Mason I. A role for FGF-8 in the initiation and maintenance of vertebrate limb bud outgrowth. Curr Biol. 5:1995;797-806.
86. Ochiya T., Sakamoto H., Tsukamoto M., Sugimura T., Terada M. Hst-1 (FGF-4) antisense oligonucleotides block murine limb development. J Cell Biol. 130:1995;997-1003.
87. Haramis A.G., Brown J.M., Zeller R. The limb deformity mutation disrupts the SHH/FGF-4 feedback loop and regulation of 5′ HoxD genes during limb pattern formation. Development. 121:1995;4237-4245.
88. Li S., Anderson R., Reginell A.D., Muneoka K. FGF-2 influences cell movements and gene expression during limb development. J Exp Zool. 274:1996;234-247.
89. Akita K., Francis-West P., Vargesson N. The ectodermal control in chick limb development Wnt-7a, Shh, Bmp-2 and Bmp-4 expression and the effect of FGF-4 on gene expression . Mech Dev. 60:1996;127-137.
90. Mima T., Ohuchi H., Noji S., Mikawa T. FGF can induce outgrowth of somatic mesoderm both inside and outside of limb-forming regions. Dev Biol. 167:1995;617-620.
91. Cohn M.J., Izpisua-Belmonte J.C., Abud H., Heath J.K., Tickle C. Fibroblast growth factors induce additional limb development from the flank of chick embryos. Cell. 80:1995;739-746.
92. Tanaka E.M., Gann A.F. Limb development The budding role of FGF . Curr Biol. 5:1995;594-597.
93. Vogel A., Rodriguez C., Izpisua-Belmonte J.C. Involvement of FGF-8 in initiation, outgrowth and patterning of the vertebrate limb. Development. 122:1996;1737-1750.
94. Abud H.E., Skinner J.A., Cohn M.J., Heath J.K. Multiple functions of fibroblast growth factors in vertebrate development. Biochem Soc Symp. 62:1996;39-50.
95. Ohuchi H., Nakagawa T., Yamamoto A., Araga A., Ohata T., Ishimaru Y., Yoshioka H., Kuwana T., Nohno T., Yamasaki M., Itoh N., Noji S. The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development. 124:1997;2235-2244.
96. Xu X., Weinstein M., Li C., Naski M., Cohen R., Ornitz D., Leder P., Deng C. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Dev Suppl. 125:1998;753-765.
97. Ingber D.E., Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro Role of extracellular matrix . J Cell Biol. 109:1989;317-330.
98. Battegay E.J. Angiogenesis Mechanistic insights, neovascular diseases, and therapeutic prospects . J Mol Med. 73:1995;333-346.
99. Sastry S.K., Horwitz A.F. Adhesion-growth factor interactions during differentiation An integrated biological response . Dev Biol. 180:1996;455-467.
100. Dealy C.N., Clarke K., Scranton V. Ability of FGFs to promote the outgrowth and proliferation of limb mesoderm is dependent on IGF-I activity. Dev Dyn. 206:1996;463-469.
101. Dealy C.N. Hensen's node provides an endogenous limb-forming signal. Dev Biol. 188:1997;216-223.
102. Madiai F., Hackshaw K.V., Chiu I.M. Characterization of the entire transcription unit of the mouse fibroblast growth factor 1 (FGF-1) gene. Tissue-specific expression of the FGF-1.A mRNA. J Biol Chem. 274:1999;11937-11944.
103. Lamb K.A., Johnson L.R., Rizzino A. NF-Y binds to the CCAAT box motif of the FGF-4 gene and promotes FGF-4 expression in embryonal carcinoma cells. Mol Reprod Dev. 48:1997;301-309.
104. Bassas L., De Pablo F., Lesniak M.A., Roth J. Ontogeny of receptors for insulin-like peptides in chick empryo tissues Early dominance of insulin-like growth factor over insulin receptors in brain . Endocrinology. 117:1985;2321-2329.
105. Kadowaki T., Koyasu S., Nishida E., Tobe K., Izumi T., Takaku F., Sakai H., Yahara I., Kasuga M. Tyrosine phosphorylation of common and specific sets of cellular proteins rapidly induced by insulin, insulin-like growth factor I, and epidermal growth factor in an intact cell. J Biol Chem. 262:1987;7342-7350.
106. Benito M., Valverde A.M., Lorenzo M. IGF-I A mitogen also involved in differentiation processes in mammalian cells . Int J Biochem Cell Biol. 28:1996;499-510.
107. Werner H., Stannard B., Bach M.A., LeRoith D., Roberts C.T. Jr. Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem Biophys Res Commun. 169:1990;1021-1027.
108. Werner H., Bach M.A., Stannard B., Roberts C.T. Jr, LeRoith D. Structural and functional analysis of the insulin-like growth factor I receptor gene promoter. Mol Endocrinol. 6:1992;1545-1558.
109. Werner H., Roberts C.T. Jr, LeRoith D. The regulation of IGF-I receptor gene expression by positive and negative zinc-finger transcription factors. Adv Exp Med Biol. 343:1993;91-103.
110. Werner H., Hernandez-Sanchez C., Karnieli E., LeRoith D. The regulation of IGF-I receptor gene expression. Int J Biochem Cell Biol. 27:1995;987-994.
111. Mamula P.W., Goldfine I.D. Cloning and characterization of the human insulin-like growth factor-I receptor gene 5′-flanking region. DNA Cell Biol. 11:1992;43-50.
112. Beitner-Johnson D., Werner H., Roberts C.T. Jr, LeRoith D. Regulation of insulin-like growth factor I receptor gene expression by Sp1 Physical and functional interactions of Sp1 at GC boxes and at a CT element . Mol Endocrinol. 9:1995;1147-1156.
113. Ohlsson C., Kley N., Werner H., LeRoith D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line Interaction between p53 and Sp1 . Endocrinology. 139:1998;1101-1107.
114. Adamo M., Roberts C.T. Jr, LeRoith D. How distinct are the insulin and insulin-like growth factor I signalling systems? Biofactors. 3:1992;151-157.
115. Gammeltoft S., Ballotti R., Kowalski A., Westermark B., Van Obberghen E. Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res. 48:1988;1233-1237.
116. Krywicki R.F., Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Res Treat. 22:1992;7-19.
117. Green B.N., Jones S.B., Streck R.D., Wood T.L., Rotwein P., Pintar J.E. Distinct expression patterns of insulin-like growth factor binding proteins 2 and 5 during fetal and postnatal development. Endocrinology. 134:1994;954-962.
118. Cross R.J., Elliott L.H., Morford L.A., Roszman T.L., McGillis J.P. Functional characterization of the insulin-like growth factor I receptor on Jurkat T cells. Cell Immunol. 160:1995;205-210.
119. Roberts CT Jr, Control of insulin-like growth factor (IGF) action by regulation of IGF-I receptor expression. Endocr J 43 (Suppl): S49-S55, 1996.
120. Boisclair Y.R., Brown A.L., Casola S., Rechler M.M. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem. 268:1993;24892-24901.
121. Giorgetti S., Ballotti R., Kowalski-Chauvel A., Tartare S., Van Obberghen E. The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem. 268:1993;7358-7364.
122. Kooijman R., Lauf J.J., Kappers A.C., Rijkers G.T. Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J Exp Med. 182:1995;593-597.
123. Nolan M.K., Jankowska L., Prisco M., Xu S., Guvakova M.A., Surmacz E. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer. 72:1997;828-834.
124. Araki E., Haag B.L. III, Matsuda K., Shichiri M., Kahn C.R. Characterization and regulation of the mouse insulin receptor substrate gene promoter. Mol Endocrinol. 9:1995;1367-1379.
125. Yamamoto K., Lapetina E.G., Moxham C.P. Insulin like growth factor-I induces limited association of phosphatidylinositol 3-kinase to its receptor. Endocrinology. 130:1992;1490-1498.
126. Liu D., Zong C.S., Wang L.H. Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions. J Virol. 67:1993;6835-6840.
127. Myers M.G. Jr, Grammer T.C., Wang L.M., Sun X.J., Pierce J.H., Blenis J., White M.F. Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem. 269:1994;28783-28789.
128. White M.F. The IRS-1 signaling system. Curr Opin Genet Dev. 4:1994;47-54.
129. Sun X.J., Wang L.M., Zhang Y., Yenush L., Myers M.G. Jr, Glasheen E., Lane W.S., Pierce J.H., White M.F. Role of IRS-2 in insulin and cytokine signalling. Nature. 377:1995;173-177.
130. Patti M.E., Sun X.J., Bruening J.C., Araki E., Lipes M.A., White M.F., Kahn C.R. 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. J Biol Chem. 270:1995;24670-24673.
131. Jiang Y., Chan J.L., Zong C.S., Wang L.H. Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. J Biol Chem. 271:1996;160-167.
132. Avivi A., Skorecki K., Yayon A., Givol D. Promoter region of the murine fibroblast growth factor receptor 2 (bek/KGFR) gene. Oncogene. 7:1992;1957-1962.
133. Kostrzewa M., Müller U. Genomic structure and complete sequence of the human FGFR4 gene. Mamm Genome. 9:1998;131-135.
134. Sheikh F., Jin Y., Pasumarthi K.B., Kardami E., Cattini P.A. Expression of fibroblast growth factor receptor-1 in rat heart H9c2 myoblasts increases cell proliferation. Mol Cell Biochem. 176:1997;89-97.
135. McEwen D.G., Ornitz D.M. Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors. J Biol Chem. 273:1998;5349-5357.
136. Miralles F., Ron D., Baiget M., Felez J., Munoz-Canoves P. Differential regulation of urokinase-type plasminogen activator expression by basic fibroblast growth factor and serum in myogenesis. Requirement of a common mitogen-activated protein kinase pathway. J Biol Chem. 273:1998;2052-2058.
137. Saito H., Kouhara H., Kasayama S., Kishimoto T., Sato B. Characterization of the promoter region of the murine fibroblast growth factor receptor 1 gene. Biochem Biophys Res Commun. 183:1992;688-693.
138. Saito H., Kouhara H., Harada T., Miyake S., Sugiyama H., Kishimoto T., Sato B. Mapping of a transcription element critical for expression of the fibroblast growth factor receptor 1 gene. Biochem Biophys Res Commun. 198:1994;1020-1026.
139. Perez-Castro A.V., Wilson J., Altherr M.R. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics. 41:1997;10-16.
140. Besser D., Presta M., Nagamine Y. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ. 6:1995;1009-1017.
141. Newberry E.P., Willis D., Latifi T., Boudreaux J.M., Towler D.A. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element. Mol Endocrinol. 11:1997;1129-1144.
142. 3 for angiogenesis. Science. 264:1994;569-571.
143. Jones J.I., Prevette T., Gockerman A., Clemmons D.R. Ligand occupancy of the αvβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor 1. Proc Natl Acad Sci USA. 93:1996;2482-2487.
144. 3. J Biol Chem. 268:1993;27371-27380.
145. v gene Identification and characterization of the promoter region . Biochim Biophys Acta. 1219:1994;228-232.
146. 3 integrin gene. Blood. 83:1994;668-676.
147. v gene promoter in mice. Biochim Biophys Acta. 1395:1998;209-219.
148. Sharma H.W., Higgins-Sochaski K., Perez J.R., Narayanan R. A DNA motif present in αV integrin promoter exhibits dual binding preference to distinct transcription factors. Anticancer Res. 15:1995;1857-1867.
149. Nogueira A.C., Neubert R., Felies A., Jacob-Muller U., Frankus E., Neubert D. Thalidomide derivatives and the immune system. 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets. Life Sci. 58:1996;337-348.
150. Blaschuk K.L., Guerin C., Holland P.C. Myoblast αvβ3 integrin levels are controlled by transcriptional regulation of expression of the β3 subunit and down-regulation of β3 subunit expression is required for skeletal muscle cell differentiation. Dev Biol. 184:1997;266-277.
151. Punglia R.S., Lu M., Hsu J., Kuroki M., Tolentino M.J., Keough K., Levy A.P., Levy N.S., Goldberg M.A., D'Amato R.J., Adamis A.P. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 46:1997;1619-1626.
152. Geitz H, Handt S and Zwingenberger K, Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 2-3: 213-221, 1996.
153. McCarty M.F. Thalidomide may impede cell migration in primates by down-regulating integrin β-chains Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis . Med Hypotheses. 49:1997;123-131.
154. Pardanaud L., Yassine F., Dieterlen-Lievre F. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development. 105:1989;473-485.
155. v integrins. Science. 270:1995;1500-1502.
156. Enenstein J., Kramer R.H. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol. 103:1994;381-386.
157. Klein S., Giancotti F.G., Presta M., Albelda S.M., Buck C.A., Rifkin D.B. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell. 4:1993;973-982.
158. 3 integrin complex on human microvascular endothelial cells. J Invest Dermatol. 103:1994;295-299.
159. Varner J.A. The role of vascular cell integrins α v β 3 and α v β 5 in angiogenesis. EXS. 79:1997;361-390.
160. 3 integrins. J Cell Sci. 105:1993;1001-1012.
161. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1995;1815-1822.
162. 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 108:1995;2655-2661.
163. Clark R.A., Tonnesen M.G., Gailit J., Cheresh D.A. Transient functional expression of αvβ3 on vascular cells during wound repair. Am J Pathol. 148:1996;1407-1421.
164. 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 93:1996;9764-9769.
165. Varner JA and Cheresh DA, Tumor angiogenesis and the role of vascular cell integrin αvβ3. In: Important Advances in Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), pp. 69-87, 1996.
166. Tang D.C., Diglio C.A., Bazaz R., Honn K.V. Transcriptional activation of endothelial cell integrin α v by protein kinase C activator 12(S)-HETE. J Cell Sci. 108:1995;2629-2644.
167. Kruse F.E., Joussen A.M., Rohrschneider K., Becker M.D., Volcker H.E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 236:1998;461-466.
168. Chilov D., Kukk E., Taira S., Jeltsch M., Kaukonen J., Palotie A., Joukov V., Alitalo K. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem. 272:1997;25176-25183.
169. Stromblad S., Cheresh D.A. Integrins, angiogenesis and vascular cell survival. Chem Biol. 3:1996;881-885.
170. Rogelj S., Klagsbrun M., Atzmon R., Kurokawa M., Haimovitz A., Fuks Z., Vlodavsky I. Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol. 109:1989;823-831.
171. WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest. 98:1996;426-433.
172. Schumacher H., Smith R.L., Williams R.T. The metabolism of thalidomide The spontaneous hydrolysis of thalidomide in solution . Br J Pharmacol. 25:1965;324-337.
173. Meise W., Ockenfels H., Köhler F. Teratologische prüfung der hydrolysenprodukte des Thalidomids. Experientia. 29:1973;423-424.
174. 12, in rabbits, rats, and monkeys. Teratology. 5:1972;233-240.
175. Bauer K.S., Dixon S.C., Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 55:1998;1827-1834.
176. Muller G.W., Chen R., Huang S.Y., Corral L.G., Wong L.M., Patterson R.T., Chen Y., Kaplan G., Stirling D.I. Amino-substituted thalidomide analogs, Potent inhibitors of TNF-α production. Bioorg Med Chem Lett. 9:1999;1625-1630.